Skip to content

The effect of oral L-arginine consumption on uterine artery resistance in women with recurrent implant failure

The effect of oral L-arginine consumption on uterine artery resistance in women with recurrent implant failure

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220317054318N1
Enrollment
72
Registered
2022-05-01
Start date
2022-05-22
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. Female infertility, unspecified

Interventions

Intervention 1: Intervention group: In the intervention group, women with recurrent implant failure, in addition to receiving drugs (including: folic acid, vitamin D3, B complex and probiotics) and st

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 41 Years

Inclusion criteria

Inclusion criteria: Infertile women aged 18-41 years Infertile IVF candidate women with a history of failure twice Women with endometrium suitable for embryo transfer Women with good quality embryos for transfer Women who have passed 2 months or more since the last ICSI test and transfer. Women who have the opportunity to attend the follow-up according to the plan and have informed consent Women with a normal size and shape of the uterus that has been confirmed by ultrasound or hysteroscopy

Exclusion criteria

Exclusion criteria: Patients who use nitrite or organic nitrate at the same time Women with chronic diseases such as: severe liver, kidney, or cardiovascular failure, patients with a history of stroke or myocardial infarction Women smokers Women with stage 3 and 4 endometriosis Women with a known etiology of implant failure such as anatomical disorders (diagnosed by hysterosalpingography), hormonal disorders, immunological disorders, trophoblasts, antiphospholipid antibodies, mutation in factor V, pro-thrombin, crew disorders Musomes are excluded from the study Patients with side effects of L-arginine Canceling the treatment cycle for any reason Unwillingness of the person to continue participating in the study

Design outcomes

Primary

MeasureTime frame
Uterine vascular resistance. Timepoint: At the beginning of the intervention and after taking L-arginine. Method of measurement: Color Doppler ultrasound.

Secondary

MeasureTime frame
Pregnancy. Timepoint: After taking the drug and transferring the fetus. Method of measurement: B-HCG titration test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShamim Pilehvari

Hamedan University of Medical Sciences

Sh.pilevar@umsha.ac.ir+98 81 3834 0266

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026